Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.


Ductal carcinoma in situ (DCIS) is the most common precursor of invasive breast cancer (IBC), with variable propensity for progression. We perform multiscale, integrated molecular profiling of DCIS with clinical outcomes by analyzing 774 DCIS samples from 542 patients with 7.3 years median follow-up from the Translational Breast Cancer Research Consortium 038 study and the Resource of Archival Breast Tissue cohorts. We identify 812 genes associated with ipsilateral recurrence within 5 years from treatment and develop a classifier that predicts DCIS or IBC recurrence in both cohorts. Pathways associated with recurrence include proliferation, immune response, and metabolism. Distinct stromal expression patterns and immune cell compositions are identified. Our multiscale approach employed in situ methods to generate a spatially resolved atlas of breast precancers, where complementary modalities can be directly compared and correlated with conventional pathology findings, disease states, and clinical outcome.

  • Anderson L
  • Angelo RM
  • Burns R
  • Cisneros L
  • Colditz GA
  • Couch F
  • Curtis C
  • DeMichele A
  • DeSchryver K
  • Ding DY
  • Gallagher K
  • Gupta GP
  • Hall A
  • Hardman T
  • Harmon B
  • Houlahan KE
  • Hwang ES
  • Jiang S
  • Khan A
  • Kilgore M
  • King LM
  • King T
  • Lee J
  • Luo J
  • Maley C
  • Marks JR
  • Matusiak M
  • McAuliffe PF
  • Nangia J
  • Owzar K
  • Polyak K
  • Risom T
  • Rivero-Gutiérrez B
  • Seoane JA
  • Simpson LA
  • Srivastava S
  • Storniolo AM
  • Strand SH
  • Straub C
  • Tappenden J
  • Thompson AM
  • Tibshirani R
  • Tseng J
  • Varma S
  • Veis DJ
  • Vennam S
  • Wang J
  • Wei S
  • West RB
  • Zhang D
  • Zhu C
  • Zhu SX
PubMed ID
Appears In
Cancer Cell, 2022, 40 (12)